RUO, Retatrutide and Regulatory Risk

Jeff Cohen says the panic among RUO websites before January stemmed from what he describes as credible rumours that regulators were preparing a major enforcement action against GLP sales. He says businesses reacted differently because each had its own tolerance for regulatory risk. Some removed GLPs entirely, while others chose to continue operating. He compares the situation to drivers exceeding the speed limit: everyone makes their own judgement about how much risk they are willing to take. Cohen says losing GLP products would mean losing a significant proportion of revenue for many businesses, so some companies adapted by expanding into telehealth, working with clinicians or diversifying their business models instead of relying solely on direct-to-consumer sales. A Path to Legitimacy According to Cohen, underground peptide businesses do have legitimate long-term pathways. He identifies two: Becoming a CGMP-certified manufacturer. Operating as a 503A or 503B compounding pharmacy. He believes regulators place significant value on recognised quality standards and encourages manufacturers to pursue certifications such as CGMP, FDA inspections, ISO standards and USP compliance to demonstrate quality and safety. The Future of 503 Pharmacies Cohen believes 503A pharmacies will continue to have a future, including for GLPs where there is an individual clinical need. He expects 503B pharmacies to continue supplying many non-GLP peptides but believes they will face increasing pressure over GLPs, particularly retatrutide, because pharmaceutical companies are heavily invested in protecting that market. Reducing Regulatory Risk Cohen says websites are often the primary trigger for FDA warning letters, cease-and-desist letters and lawsuits. He recommends avoiding: Claims about health outcomes or expected results. References to pharmaceutical brand names or ingredient names. Content that promotes human use while simultaneously marketing products as research use only. He says narrowing a website’s public content reduces the likelihood of becoming an enforcement target. Growing Scrutiny Beyond Websites Cohen believes regulatory attention is extending beyond websites into educational platforms and clinician activity. He cites media reporting on compounded retatrutide as evidence that public opinion is being shaped ahead of broader enforcement. He argues that clinicians routinely prescribe compounded, off-label and experimental medications as part of medical practice, but believes retatrutide is receiving exceptional scrutiny because pharmaceutical companies are preparing to protect the market once approval is granted. Retatrutide’s Future Cohen predicts retatrutide will become one of the most valuable products in the peptide market. He says that if retatrutide were ever classified as a biologic, only the pharmaceutical manufacturer would be permitted to produce it, preventing compounding pharmacies from supplying it. In his view, this would reduce availability, increase demand and drive prices significantly higher for consumers.